SCHEMBL112775

SCHEMBL112775

CSc1nccc(Nc2nc3ccc(Br)cc3s2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.48
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
DYRK1A Q13627 1/20 0.48
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
CYP2D6 P10635 1/20 0.42
KMT2A Q03164 1/20 0.42
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
LCK P06239 3/20 0.39
PKM P14618 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
APP P05067 1/20 0.39
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL808047 0.81 LCK (0.53) RAB9ANPC1CYP1A2CYP3A4CYP2C9
SCHEMBL112798 0.79 RAB9A (0.49) RAB9ANPC1CYP1A2CYP3A4CYP2C9
SCHEMBL113211 0.78 RAB9A (0.46) RAB9ANPC1CYP1A2CYP3A4CYP2C9
SCHEMBL8739182 0.76 LCK (0.54) RAB9ANPC1CYP1A2CYP3A4CYP2C9
SCHEMBL29470520 0.76 LCK (0.54) RAB9ANPC1CYP1A2CYP3A4CYP2C9
SCHEMBL29470475 0.73 RAB9A (0.48) RAB9ANPC1CYP1A2CYP3A4CYP2C9
SCHEMBL15673444 0.73 RAB9A (0.48) RAB9ANPC1CYP1A2CYP3A4CYP2C9
SCHEMBL8739547 0.73 LCK (0.56) RAB9ANPC1CYP1A2CYP3A4CYP2C9
SCHEMBL2369646 0.72 RAB9A (0.49) RAB9ANPC1CYP1A2CYP3A4CYP2C9
SCHEMBL28661987 0.72 MEN1 (0.39) RAB9ANPC1CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
EP-2408769-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS Glaxo Group Limited (GB) 2012-01-25 EP disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK PIK3CA 147/4885RAB9A 3413/4885NPC1 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.